Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

被引：18
|
作者：
Kaul, Sanjay [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, 8635 W Third St,Ste 790W, Los Angeles, CA 90048 USA
来源：
CIRCULATION | 2016年 / 134卷 / 02期
关键词：
clinical trial; diabetes mellitus; mortality; TRIAL;
D O I：
10.1161/CIRCULATIONAHA.116.022537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：94 / +
页数：11
相关论文
共 50 条
  • [31] EMPAGLIFLOZIN REDUCES URINARY MITOCHONDRIAL DNA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Lee, Haekyung
    Yang, Wonmi
    Kim, Hyoungnae
    Jeon, Jin Seok
    Noh, Hyunjin
    Han, Dong Cheol
    Byun, Dong Won
    Kim, Hye Jeong
    Suh, Kyoil
    Park, Hyeong Kyu
    Kwon, Soon Hyo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1339 - 1339
  • [32] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Kinduryte Schorling, Ona
    Clark, Douglas
    Zwiener, Isabella
    Kaspers, Stefan
    Lee, Jisoo
    Iliev, Hristo
    ADVANCES IN THERAPY, 2020, 37 (08) : 3463 - 3484
  • [33] Erratum to: Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
    Lesley J. Scott
    Drugs, 2015, 75 : 141 - 141
  • [34] Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus
    Inzucchi, S. E.
    Zinman, B.
    Lachin, J. M.
    Wanner, C.
    Ferrari, R.
    Bluhmki, E.
    Hantel, S.
    Johansen, O.
    Woerle, H. -J.
    Broedl, U. C.
    DIABETOLOGIA, 2013, 56 : S378 - S378
  • [35] Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients
    Jamalizadeh, Mahdieh
    Hasanzad, Mandana
    Sarhangi, Negar
    Sharifi, Farshad
    Nasli-Esfahani, Ensieh
    Larijani, Bagher
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2021, 20 (02) : 1407 - 1413
  • [36] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Ona Kinduryte Schorling
    Douglas Clark
    Isabella Zwiener
    Stefan Kaspers
    Jisoo Lee
    Hristo Iliev
    Advances in Therapy, 2020, 37 : 3463 - 3484
  • [37] Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus
    Grabarczyk, Ted Robert
    Wissman, Natalie Koury
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (10) : 981 - 987
  • [38] Utilization of Empagliflozin in Patients with Type 2 Diabetes Mellitus and Congestive Heart Failure
    Alvarez, Carlos A.
    Perkins, Aaron
    Sigler, Meredith A.
    Yang, Hui
    Caberwal, Harjeet
    Ebrahimi, Ramin
    DIABETES, 2023, 72
  • [39] Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
    Anker, Stefan D.
    Sander, Leif-Erik
    Fitchett, David H.
    Zinman, Bernard
    Ofstad, Anne Pernille
    Wanner, Christoph
    Vedin, Ola
    Lauer, Sabine
    Verma, Subodh
    Yaggi, Henry K.
    Inzucchi, Silvio E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [40] Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
    Triplitt, C.
    Solis-Herrera, C.
    Cersosimo, E.
    Abdul-Ghani, M.
    Defronzo, Ralph A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (18) : 2819 - 2833
12345